Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma

被引：5

作者：

Jenkins, Russell W. ^{[1
,2
]}

Barbie, David A. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Div Med Oncol, Boston, MA USA

来源：

CANCER DISCOVERY | 2017年 / 7卷 / 08期

关键词：

RESISTANCE; INHIBITORS; MITF; NRAS;

D O I：

10.1158/2159-8290.CD-17-0607

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Identifying molecular and cellular features associated with resistance to targeted BRAF/MAPK pathway inhibition may guide development of novel therapeutic approaches. Integrated, comparative analysis of genomic and functional data in sensitive and resistant cell lines unveils novel targetable regulators of resistance to MAPK pathway inhibition in melanoma.

引用

页码：799 / 801

页数：3

共 50 条

[41] Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma
Sabbatino, Francesco
Wang, Yangyang
Scognamiglio, Giosue
Favoino, Elvira
Feldman, Steven A.
Villani, Vincenzo
Flaherty, Keith T.
Nota, Sjoerd
Giannarelli, Diana
Simeone, Ester
Anniciello, Anna M.
Palmieri, Giuseppe
Pepe, Stefano
Botti, Gerardo
Ascierto, Paolo A.
Ferrone, Cristina R.
Ferrone, Soldano
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (07):
[42] Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma
F. Aya
A. Fernandez-Martinez
L. Gaba
I. Victoria
M. Tosca
E. Pineda
P. Gascon
A. Prat
A. Arance
Clinical and Translational Oncology, 2017, 19 : 119 - 124
[43] BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma
Paoluzzi, Luca
Hanniford, Douglas
Sokolova, Elena
Osman, Iman
Darvishian, Farbod
Wang, Jinhua
Bradner, James E.
Hernando, Eva
CANCER MEDICINE, 2016, 5 (06): : 1183 - 1193
[44] BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma
Bai, X.
Mao, L. L.
Chi, Z. H.
Sheng, X. N.
Gui, C. L.
Kong, Y.
Dai, J.
Wang, X.
Li, S. M.
Tang, B. X.
Lian, B.
Zhou, L.
Yan, X. Q.
Guo, J.
Si, L.
NEOPLASMA, 2017, 64 (04) : 626 - 632
[45] Which drug, and when, for patients with BRAF-mutant melanoma?
Jang, Sekwon
Atkins, Michael B.
LANCET ONCOLOGY, 2013, 14 (02): : E60 - E69
[46] Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto
Pier Francesco Ferrucci
Rosalie Fisher
Michele Del Vecchio
Victoria Atkinson
Henrik Schmidt
Jacob Schachter
Paola Queirolo
Georgina V. Long
Anna Maria Di Giacomo
Inge Marie Svane
Michal Lotem
Gil Bar-Sela
Felix Couture
Bijoyesh Mookerjee
Razi Ghori
Nageatte Ibrahim
Blanca Homet Moreno
Antoni Ribas
Nature Medicine, 2019, 25 : 941 - 946
[47] Mitochondrial biogenesis meets chemoresistance in BRAF-mutant melanoma
Wu, Lawrence W.
Zhang, Gao
Herlyn, Meenhard
MOLECULAR & CELLULAR ONCOLOGY, 2016, 3 (04):
[48] Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Ascierto, Paolo Antonio
Ferrucci, Pier Francesco
Fisher, Rosalie
Del Vecchio, Michele
Atkinson, Victoria
Schmidt, Henrik
Schachter, Jacob
Queirolo, Paola
Long, Georgina V.
Di Giacomo, Anna Maria
Svane, Inge Marie
Lotem, Michal
Bar-Sela, Gil
Couture, Felix
Mookerjee, Bijoyesh
Ghori, Razi
Ibrahim, Nageatte
Moreno, Blanca Homet
Ribas, Antoni
NATURE MEDICINE, 2019, 25 (06) : 941 - +
[49] Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy
Atkins, Michael B.
Julian, Cristina
Secrest, Matthew H.
Lee, Janet
Abajo-Guijarro, Ana M.
McKenna, Edward
FUTURE ONCOLOGY, 2022, 18 (18) : 2233 - 2245
[50] Combined Targeted Therapy for BRAF-Mutant, Treatment-Related Acute Myeloid Leukemia
Wander, Seth A.
Hasserjian, Robert P.
Oduro, Kwadwo
Glomski, Krzysztof
Nardi, Valentina
Cote, Gregory M.
Graubert, Timothy A.
Brunner, Andrew M.
Chen, Yi-Bin A.
Fathi, Amir T.
JCO PRECISION ONCOLOGY, 2017, 1 : 1 - 7

← 1 2 3 4 5 →